Nifty Midcap Select News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Aurobindo Pharma Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news and updates on Nifty Midcap Select from all sources in a single place.

Load latest

Aurobindo Pharma Ltd.

04 Jul 2025

1122.80

0.78%

AUROBINDO PHARMA LTD

Buy: Aurobindo Pharma Ltd.

Target

Geojit BNP Paribas

with multiple regulatory milestones lined up in the coming quarters. Execution of the pipeline delivery and expansion initiatives is expected to support long-term value creation. Therefore, we maintain our rating on the stock at BUY, with rolledforward target price of Rs. 1,348, based on 17.5x FY27x Adj. EPS....

Aurobindo Pharma Ltd. is trading below all available SMAs

Marico Ltd.

04 Jul 2025

693.95

-1.83%

Good start to FY26

Buy: Marico Ltd.

Sharekhan

We retain a Buy rating on Marico with an unchanged PT of Rs. 825. The stock trades at 51x/44x its FY26E/FY27E EPS, respectively.

Number of FII/FPI investors increased from 881 to 1031 in Jun 2025 qtr.

Oracle Financial Services Software Ltd.

03 Jul 2025

8609.00

-3.69%

Oracle, OpenAI expand Stargate deal to build more US data centres

Business Standard

Oracle shares gained as much as 3.9 per cent to $227.46, a record high, following the news. The stock has jumped 36 per cent this year, fueled by investor enthusiasm in its cloud business